8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Sep 12, 2017)

Filed September 12, 2017For Securities:ELV

Summary

This 8-K filing by Elevance Health, Inc. (formerly Anthem, Inc.) announces that company officers will be speaking with investors between September 12 and September 29, 2017. During these discussions, the company intends to reaffirm its net income guidance for the full year 2017. The reaffirmed guidance indicates a net income expected to be greater than $10.35 per share, which includes approximately $1.35 per share of net unfavorable items. Excluding these specific items, the company anticipates adjusted net income to be greater than $11.70 per share. This guidance explicitly excludes any adjustment items beyond those already reported in the company's second quarter 2017 earnings release.

Key Highlights

  • 1Elevance Health (Anthem, Inc.) reaffirming its full-year 2017 net income guidance to investors.
  • 2Full-year 2017 net income guidance projected to be greater than $10.35 per share.
  • 3Guidance includes approximately $1.35 per share of net unfavorable items.
  • 4Adjusted net income guidance (excluding unfavorable items) expected to be greater than $11.70 per share.
  • 5Guidance does not incorporate any new adjustment items beyond those disclosed in Q2 2017 earnings.
  • 6The disclosure is made under Regulation FD and is not considered 'filed' for Section 18 purposes.
  • 7The document includes a standard 'forward-looking statements' disclaimer detailing various risks and uncertainties.

Frequently Asked Questions

The primary purpose of this 8-K filing is to publicly disclose that Elevance Health (Anthem, Inc.) officers will be meeting with investors and will be reaffirming the company's financial guidance for the full fiscal year 2017.

The company is reaffirming its guidance for full-year 2017 net income to be greater than $10.35 per share. This includes about $1.35 per share from net unfavorable items. Excluding these items, the adjusted net income is expected to be greater than $11.70 per share.

No, the reaffirmed guidance explicitly states that it does not include any adjustment items beyond those that were already reported in the company's second quarter 2017 earnings release.

No, the information furnished under Item 7.01 (Regulation FD Disclosure) is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into future SEC filings unless expressly stated.